Download Pinto, A. K., A. M. Jamieson, D. H. Raulet, and A. B. Hill. 2007. The role of NKG2D signaling in inhibition of cytotoxic T-lymphocyte lysis by the Murine cytomegalovirus immunoevasin m152/gp40. J. Viro 81:12564-12571 .

JOURNAL OF VIROLOGY, Nov. 2007, p. 12564–12571
0022-538X/07/$08.00⫹0 doi:10.1128/JVI.01328-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.
Vol. 81, No. 22
The Role of NKG2D Signaling in Inhibition of Cytotoxic T-Lymphocyte
Lysis by the Murine Cytomegalovirus Immunoevasin m152/gp40䌤
Amelia K. Pinto,1 Amanda M. Jamieson,2 David H. Raulet,2 and Ann B. Hill1*
Department of Molecular Microbiology and Immunology (L220), Oregon Health and Science University,
3181 SW Sam Jackson Park Rd., Portland, Oregon 97239,1 and Department of Molecular and
Cell Biology, University of California, 485 LSA, Berkeley, Berkeley, California 947202
Received 18 June 2007/Accepted 31 August 2007
Three proteins encoded by murine cytomegalovirus (MCMV)— gp34, encoded by m04 (m04/gp34), gp48, encoded
by m06 (m06/gp48), and gp40, encoded by m152 (m152/gp40)—act together to powerfully impact the ability of
primed cytotoxic CD8 T lymphocytes (CTL) to kill virus-infected cells. Of these three, the impact of m152/gp40 on
CTL lysis appears greater than would be expected based on its impact on cell surface major histocompatibility
complex (MHC) class I. In addition to MHC class I, m152/gp40 also downregulates the RAE-1 family of NKG2D
ligands, which can provide costimulation for CD8 T cells. We hypothesized that m152/gp40 may impact CTL lysis
so profoundly because it inhibits both antigen presentation and NKG2D-mediated costimulation. We therefore
tested the extent to which m152/gp40’s ability to inhibit CTL lysis of MCMV-infected cells could be accounted for
by its inhibition of NKG2D signaling. As was predictable from the results reported in the literature, NKG2D ligands
were not detected by NKG2D tetramer staining of cells infected with wild-type MCMV, whereas those infected with
MCMV lacking m152/gp40 displayed measurable levels of the NKG2D ligand. To determine whether NKG2D
signaling contributed to the ability of CTL to lyse these cells, we used a blocking anti-NKG2D antibody. Blocking
NKG2D signaling did affect the killing of MCMV-infected cells for some epitopes. However, for all epitopes, the
impact of m152/gp40 on CTL lysis was much greater than the impact of inhibition of NKG2D signaling. We conclude
that the downregulation of NKG2D ligands by MCMV makes only a small contribution to the impact of m152/gp40
on CTL lysis and only for a small subset of CTL.
All cytomegaloviruses (CMVs) interfere with the major histocompatibility complex (MHC) class I pathway of antigen
presentation. Although the biological ramifications of this interference remain unclear, the variety of molecular mechanisms employed by different CMVs to attack MHC class I is
impressive. Murine CMV (MCMV) contains three viral genes
whose products interfere with MHC class I: m04/gp34, m06/
gp48, and m152/gp40 (37). This interference has been demonstrated by their ability to impair the lysis of infected targets by
cytotoxic T-lymphocytes (CTL) (17, 31).
m06/gp48 binds MHC class I and diverts it to lysosomes for
destruction (33). m152/gp40 causes nascent MHC class I to be
retained in the endoplasmic reticulum cis-Golgi intermediate
compartment (6, 34, 38). m04/gp34 binds some MHC class I
and escorts it to the cell surface; in different circumstances,
m04/gp34 can either increase or decrease susceptibility to CTL
lysis (17, 21, 30, 31). Both m06/gp48 and m152/gp40 reduce the
cell surface expression of MHC class I, whereas m04/gp34
either has no impact on cell surface MHC class I or slightly
elevates the levels (22, 31, 35). We recently assessed the relative impacts of the three MHC class I immune evasion genes
on the ability of CTL specific for 15 H-2b-restricted epitopes to
lyse infected cells (31). This study revealed that the three genes
act powerfully together to impair CTL lysis of infected cells.
We used a panel of mutant viruses generated by Wagner et al.
(35) in which m04, m06, and m152 are deleted either alone or
* Corresponding author. Mailing address: 3181 SW Sam Jackson
Park Rd., Portland, OR 97239. Phone: (503) 494-0763. Fax: (503)
494-6862. E-mail: [email protected].
䌤
Published ahead of print on 12 September 2007.
in combination. This revealed that m06/gp48 and m152/gp40
made the major contribution to this inhibition, with a contribution from m04/gp34 being needed only for certain epitopes.
Thus, the two genes that downregulate cell surface MHC class
I also had the greatest impact on CTL lysis.
However, the degree of cell surface MHC class I downregulation did not correlate precisely with the inhibition of CTL
lysis. This was most marked in the case of m152/gp40, which
had only a moderate impact on the endoplasmic reticulum
export of nascent MHC class I and on cell surface MHC class
I levels but had a profound impact on CTL lysis. The fact that
m152/gp40’s impact on CTL lysis was greater than would be
expected from its impact on cell surface MHC class I was also
noted by Wagner et al. in the original description of their panel
of immunoevasin-deficient viruses. These authors postulated
that the discrepancy might be explained by a recently uncovered second function of m152/gp40, namely, its ability to prevent the expression of the RAE-1 family of ligands for NKG2D
(23, 26).
NKG2D is an activating receptor found on natural killer
(NK) cells and on antigen-experienced CD8 T cells. Most
NKG2D ligands are not constitutively expressed but are induced by transformation or stress, notably by viral infection (1,
12). In the mouse, there are three groups of known NKG2D
ligands, the RAE-1 family of molecules, H-60, and MULT-1
(5, 8, 9). These molecules are major targets of CMV immune
evasion: four MCMV genes (m138, m145, m152, and m155)
are involved in preventing their expression on infected cells
(16, 23–25, 27). The downregulation of the individual NKG2D
ligands by each of these MCMV genes affects the ability of NK
cells to control MCMV infection (16, 23–27).
12564
VOL. 81, 2007
NKG2D SIGNALING IN CTL LYSIS OF MCMV-INFECTED CELLS
m152/gp40 prevents the expression of the RAE-1 family of
ligands for NKG2D (23). Thus, m152/gp40 has at least two
targets: MHC class I and RAE-1 molecules. Although it is best
characterized as a major activating receptor on NK cells,
NKG2D does also function as a costimulatory molecule on
CD8 T cells (19). In fact, for two human CMV (HCMV)specific CTL clones, costimulation through NKG2D was necessary to enable the lysis of infected targets once the HCMV
immune evasion genes had downregulated MHC class I (14).
We therefore wondered whether the apparently disproportionate impact of m152/gp40 on CTL lysis could be explained by its
ability to inhibit RAE-1 expression, depriving the CTL of
NKG2D-mediated costimulation.
The purpose of the present study was to test the hypothesis
that NKG2D inhibition contributes to the profound impact of
m152/gp40 on the ability of CD8 T cells to lyse MCMV-infected targets. Although all MCMV-specific CD8 T cells come
to express NKG2D over time, we found that costimulation by
the NKG2D ligand RAE-1 played only a small role in promoting CTL lysis and only for a subset of epitope specificities. For
this minority of specificities, the inhibition of NKG2D signaling did contribute to m152/gp40’s impact on CTL lysis. Contrary to our initial hypothesis, overall, targeting of NKG2D
does not play a major role in m152/gp40’s impact on CD8
T-cell killing.
MATERIALS AND METHODS
Cells. IC-21 cells (a simian virus 40-transformed macrophage cell line from
C57BL/6 mice [4], a gift from Ann Campbell, Eastern Virginia Medical School)
were cultured in RPMI medium supplemented with 10% fetal bovine serum
(FBS), 2 mM L-glutamine, 10 mM HEPES, 1 mM sodium pyruvate, 4.5 g/liter
glucose, 1.5 g/liter sodium bicarbonate, and antibiotics. K42 cells (simian virus
40-transformed H-2b fibroblasts, a gift from Marek Michalak, University of
Alberta), C57BL/6 mouse embryo fibroblasts (MEFs) (isolated from C57BL/6
mice), BALB/c MEFs (isolated from BALB/c mice), L929 cells (ATCC), and
B16-FL cells (murine melanoma tumor cell line producing FLT-3 ligand [11], a
gift from Glen Dranoff, Harvard Medical School) were cultured in Dulbecco’s
modified Eagle’s medium supplemented with 10% FBS and antibiotics. The L929
supernatant, a source of macrophage colony-stimulating factor, was harvested
from L929 cells grown for 10 days after reaching confluence. Primary bone
marrow macrophages (BMM⌽) were isolated by the procedure described by
Bouwer et al. (2). Briefly, bone marrow was cultured on non-tissue-culturetreated petri dishes in Dulbecco’s modified Eagle’s medium with 10% FBS, 30%
macrophage colony-stimulating factor from L929 supernatant, and antibiotics.
Lymphokine-activated killer (LAK) cells were prepared by incubating C57BL/6
mouse splenocytes for 4 days in RPMI complete medium containing 1 ␮g/ml
interleukin-2.
Viruses. Wild-type bacterial artificial chromosome-derived MCMV strain
MW97.01 (36) ⌬m04, ⌬m06, ⌬m152 ⌬m04⫹m06, ⌬m04⫹m152, ⌬m06⫹m152,
and ⌬m04⫹m06⫹m152 (35) mutant viruses were grown in C57BL/6 MEFs and
then purified by being pelleted over a 15% sucrose cushion (3). Each virus stock
was titered without centrifugal enhancement on BALB/3T3 cells. The mean of
the results of three virus titrations was used to calculate titers for use in these
assays.
T-cell lines. Female C57BL/6 or BALB/c mice were purchased from NCI
Fredrick (Baltimore, MD) or The Jackson Laboratory (Bar Harbor, ME) and
infected with either 1 ⫻ 106 or 5 ⫻ 106 PFU of MCMV. Spleens were harvested
from mice that had been infected at least 11 weeks previously. As a source of
dendritic cell-enriched splenocytes to stimulate CTL lines, we used spleens from
mice that had been injected 14 days previously with the Flt-3 ligand-secreting
B16-FL tumor cells. Splenocytes from the B16-FL-cell-injected mice were
gamma irradiated, pulsed with peptide at 10⫺8 M, and cultured with splenocytes
from MCMV-infected mice in RPMI supplemented with 10% FBS for 3 days,
after which 10 U/ml recombinant interleukin-2 (eBioscience) was added. After
10 days, the percentage of CD8 T cells responding to the stimulating peptide
12565
epitopes was assessed by intracellular cytokine staining (ICS), and the cells used
in 51Cr release assays.
Antibodies and tetramers. Anti-gB and anti-gH were a gift from Lambert Loh
(28, 29, 32). Anti-NKG2D (MI-6) (19) and anti-pp89 (7) were purified on protein
A and G (Sigma-Aldrich) columns and conjugated to fluorescein isothiocyanate
(Molecular Probes), phycoerythrin, or allophycocyanin (Cyanotech) according to
published protocols (15). Anti-gamma interferon (IFN-␥) (XMG1.2) and antiCD8 (53-6.7) were purchased from eBioscience. Anti-MULT-1 (237104), antiRAE-1pan-specific (186107), and anti-H60 (205326) were purchased from R&D
Systems and used according to the manufacturer’s instructions. Staining with
NKG2D tetramers was done as previously described (9). Db-M45 tetramers,
generated as previously described (13), and M38, m139, and m141 tetramers, a
kind gift from Sophie Sierro and Paul Klenerman (University of Oxford, Oxford,
United Kingdom) were coupled to streptavidin-phycoerythrin.
FACS analysis. IC-21 cells were infected overnight with the panel of mutant
viruses at a multiplicity of infection of 20 in the presence of 0.3 mg/ml phosphonoacetic acid (PAA) (Sigma-Aldrich). PAA is used to limit cytopathic effect by
blocking late gene expression. We have previously reported that PAA does not
alter immune evasion gene function in macrophages (30). For intranuclear staining, cells were stained with tetramer specific for anti-NKG2D ligands, fixed with
CytoFix/CytoPerm (BD Bioscience), and then permeabilized by incubation for 5
min with 0.1% Triton X-100 (Sigma-Aldrich) in phosphate-buffered saline. The
cells were then stained for 30 min with anti-pp89 in the presence of 0.1% Triton
X-100. The cells were washed three times in 0.1% Triton X-100 and then washed
one time in fluorescence-activated cell sorter (FACS) buffer before analysis. ICS
was used to demonstrate the antigen specificity. For ICS, CD8 T-cell lines were
incubated with their appropriate peptide at 1 ␮M in the presence of brefeldin A
(Golgi-plug; BD Bioscience) for 6 h, stained with anti-CD8 and anti-NKG2D,
fixed with CytoFix/CytoPerm (BD Bioscience), permeabilized with PermWash
(BD Bioscience), and stained with anti-IFN-␥. All cells were analyzed by using a
FACSCalibur flow cytometer (BD Bioscience) in conjunction with Cell Quest
(BD Bioscience). All further analysis was performed using FlowJo software
(Treestar).
Assay for cell-mediated cytotoxicity. Amounts of 104 MEF IC-21, K42, or
BMM⌽ target cells per well were plated in 96-well plates, infected with the
indicated viruses at a multiplicity of infection of 20, and labeled with 100 ␮Ci
51
Cr (NEN) in the presence of 0.3 mg/ml of PAA for 12 h. For peptide-pulsed
targets, 51Cr-labeled cells were incubated with 1 ␮M peptide for 1 h at 37°C and
then washed three times. Effector T cells were incubated with the appropriate
concentration of anti-NKG2D (MI-6) or isotype control immunoglobulin G
(IgG) for 1 h, and then the effector cells were added at the indicated effectorto-target (E/T) ratios in the presence of blocking antibody or control antibody.
The cells were incubated for 6 h, and the supernatants were harvested and
assayed with a Topcount scintillation counter (Packard Instruments). The background 51Cr release was determined by incubating targets with medium alone,
and the total 51Cr release by lysing targets with medium containing 1% Nonidet
P-40 (USB). The percent specific lysis was calculated as follows: (experimental
counts per minute [cpm] ⫺ background cpm)/(total cpm ⫺ background cpm).
Statistics. The statistical significance was determined by using Student’s t test.
A paired two-tailed t test was used, and all comparisons were determined to be
of equal variance.
RESULTS
NKG2D is expressed on MCMV-specific CD8 T cells in vivo
and in vitro. According to the literature, NKG2D is expressed
on murine CD8 T cells within several days of activation (10).
Because CMV-specific memory CD8 T cells have an unusual
phenotype and usually fail to express the costimulatory molecules CD28 and CD27, we first assessed whether MCMVspecific CD8 T cells express NKG2D. C57BL/6 mice were
infected with MCMV and then sacrificed at various times
postinfection. MCMV-specific responses were assessed by ICS
for IFN-␥, and NKG2D expression determined by costaining
with the NKG2D-specific antibody (Fig. 1A). Figure 1B shows
that the rate of acquisition of NKG2D differed for different
epitope-specific responses. CD8 T cells specific for m139 and
m141 were mostly NKG2D positive from day 7 postinfection,
whereas it took 30 days before the majority of CD8 T cells
12566
PINTO ET AL.
J. VIROL.
FIG. 2. m152 interferes with expression of NKG2D ligands on infected IC-21 macrophages. IC-21 cells were infected with the indicated
viruses, stained with NKG2D tetramers, and analyzed by FACS. For
each infected cell type, NKG2D-tetramer staining of uninfected cells is
shown in gray for comparison.
FIG. 1. Expression of NKG2D by MCMV-specific CD8 T cells. (A)
Splenocytes from five mice infected 7 days previously were stimulated with
the indicated peptides for ICS. The left panels show CD8 and NKG2D
staining from a representative animal and from a naı̈ve control. The numbers
indicate the percentage of lymphocytes that express CD8, NKG2D, or both.
The middle panels are gated on CD8⫹ cells, and the numbers show the IFN-␥
response to the indicated peptides from a representative infected mouse. The
numbers indicate the percentage of lymphocytes that express CD8, and the
numbers in the upper quadrant indicate the CD8 T cells that are secreting
IFN-␥. The right panels show the number of IFN-␥-positive cells stained with
NKG2D. (B) Percent CD8 T cells specific for the indicated peptides that
expressed NKG2D on the indicated days postinfection. The means ⫾ standard deviations of the results for 5 mice per group are shown. (C) Polyclonal
T-cell lines were generated against the indicated peptide epitopes and analyzed by FACS 10 days later. Antigen-specific cells were identified by tetramer staining (top panel), with the numbers representing the CD8 T cells
that stained positive or negative for each antigen-specific tetramer. NKG2D
expression on tetramer-positive cells is shown below, as indicated by the
numbers for each FACS plot.
specific for M38 and M45 expressed NKG2D. However, most
antigen-specific CD8 T cells continued to express NKG2D at
123 days postinfection.
The phenomenon of m152/gp40’s disproportionate impact
on CTL lysis, which we wanted to address in these experiments,
was described by using in vitro CTL lines. To confirm that
NKG2D expression was maintained upon culture, we generated short-term polyclonal CTL lines specific for four epitopes
and assessed their NKG2D expression. Figure 1C shows that
the majority of cells in these lines continued to express
NKG2D.
Impact of m04/gp34, m06/gp48, and m152/gp40 on expression of NKG2D ligands in infected macrophages. As described
above, m152/gp40 has been shown to downregulate the RAE-1
family of NKG2D ligands. Neither m04/gp34 nor m06/gp48 has
been reported to have any impact on NKG2D ligands. However, the previous reports of the downregulation of NKG2D
ligands by m152/gp40 have all been carried out in infected
fibroblasts. Because our recent characterization of the impact
of immune evasion genes on CTL lysis was performed using
the macrophage cell line IC-21, we wanted to confirm that
m152/gp40 impacted RAE-1 expression in this cell line. Staining with NKG2D tetramers demonstrated that IC-21 cells constitutively express NKG2D ligands (Fig. 2). Upon infection
with MCMV, the expression was downregulated, and this
downregulation was not relieved by infection with viruses lacking m04 or m06. However, infection with MCMV lacking m152
allowed the expression of NKG2D at almost the same level as
in uninfected cells. Three other MCMV genes, m145, m155,
and m138, are known to downregulate one or both of the
NKG2D ligands MULT-1 and H60 (16, 24, 25, 27). The fact
that, in IC-21 cells, infection with a virus lacking m152 restored
NKG2D ligand expression to a level similar to that observed in
uninfected cells suggested that RAE-1 molecules are the predominant NKG2D ligand expressed by IC-21 cells. This was
confirmed by staining both infected and uninfected cells with
antibodies against MULT-1, H60, and RAE-1 antibodies (data
not shown).
Impact of NKG2D blockade on the ability of CTL to lyse
MCMV-infected cells. In order to assess the extent to which
m152/gp40’s ability to inhibit CTL lysis can be attributed to its
downregulation of NKG2D ligands, we used the blocking antiNKG2D antibody (MI-6) to inhibit CTL lysis. We first determined the concentration of anti-NKG2D that could completely
inhibit NKG2D signaling by titrating anti-NKG2D in a 51Cr
release assay using LAK cells against two cell lines that constitutively express NKG2D ligands: IC-21 cells and K42 cells.
VOL. 81, 2007
NKG2D SIGNALING IN CTL LYSIS OF MCMV-INFECTED CELLS
FIG. 3. Determining the anti-NKG2D antibody concentration
needed to completely inhibit NKG2D signaling. Two cell lines, IC-21
macrophages and K42 fibroblasts, constitutively expressed NKG2D
ligands. (A) To identify the concentration of anti-NKG2D antibody
needed to completely inhibit NK cells lysis, LAK cells were incubated
with the targets in the presence of the indicated concentration of
antibody at an E/T ratio of 20:1 for a 51Cr release assay. (B) E/T ratio
titration of LAK cells with IC-21 cells and K42 targets at 50 ␮g/ml of
anti-NKG2D antibody or control.
Figure 3 shows that maximal inhibition of lysis was achieved
using an antibody concentration of 50 ␮g/ml. We note that this
concentration did not completely inhibit LAK lysis of IC-21
cells, presumably because other non-NKG2D-mediated LAK
receptors are involved in the killing of that cell line (19). We
concluded that anti-NKG2D at a concentration of 50 ␮g/ml
could be used to block NKG2D signaling.
We then tested the impact of NKG2D blockade on the
ability of MCMV-specific CTL to lyse IC-21 cells infected with
the panel of immunoevasin-deficient MCMV viruses created
by Wagner et al. (35). Short-term polyclonal CTL lines were
tested in 51Cr release assays against targets incubated with
anti-NKG2D or rat IgG at 50 ␮g/ml. The results of a typical
assay are shown in Fig. 4A. We tested CTL lines against eight
different epitope specificities, and each epitope specificity was
tested at least three times. To integrate the data from multiple
assays, the results for each assay were normalized, with the lysis
of each of the mutants, with or without anti-NKG2D, expressed as a percentage of the lysis in cells infected with
⌬m04⫹m06⫹m152 in the presence of rat IgG. An E/T ratio
that was below the plateau of maximum killing was used for the
calculation. The mean and standard error of multiple assays
were then calculated.
Figure 4B shows the results of these normalized assays for
eight CTL specificities. In the cases where NKG2D blockade
resulted in reduced CTL lysis, significant reduction of lysis by
the addition of NKG2D is shown as indicated in the figure
legend. The impact of NKG2D blockade was most clearly seen
for M97-specific CTL. Importantly, NKG2D blockade reduced
the lysis of targets infected with viruses that lacked m152 but
not of targets infected with viruses in which m152 was present.
This result is consistent with the above observation that IC-21
cells infected with a virus containing m152 do not express
ligands capable of engaging NKG2D.
Several other H2-Kb CTL specificities, M38, m139, and
12567
m141, also showed a significant impact of NKG2D blockade in
some but not all viruses lacking m152. However, we saw no
impact of NKG2D blockade on any of the H2-Db epitope
specificities we tested. For the majority of epitope-specific CTL
tested, NKG2D blockade in the absence of m152/gp40 did not
cause a significant reduction of target lysis.
Contribution of NKG2D blockade to m152/gp40’s impact on
CTL lysis. For those CTL that were affected by NKG2D blockade, we were interested in determining how much of m152/
gp40’s impact could be attributed to its impact on NKG2D
signaling. Figure 4C shows the normalized results from Fig. 4B,
redisplayed in order to contrast the impact of m152/gp40 with
the impact of NKG2D blockade. Even for the specificities that
were most impacted by NKG2D blockade, such as M97, the
addition of m152/gp40 caused a greater reduction of target cell
lysis than was achieved by NKG2D blockade alone (e.g., for
M97, 85% lysis by the ⌬m04⫹m06⫹m152 mutant virus in the
presence of anti-NKG2D compared with 25% lysis by the
⌬m04 m06 mutant virus). We conclude that NKG2D blockade
contributes only modestly to m152/gp40’s impact on CTL lysis
and then only for a minority of epitopes.
This investigation was prompted in part by the observation
that m06/gp48 has a greater impact on cell surface MHC class
I levels than m152/gp40 but generally has less impact on CTL
lysis. In order to compare the impact of m152/gp40 and m06/
gp48 on CTL lysis with m152/gp40’s impact on NKG2D signaling taken out of the picture, we graphed the lysis of cells
infected with ⌬m04⫹m06 (m152/gp40 acting alone) and
⌬m04⫹m152 (m06/gp48 acting alone) mutant viruses, both in
the presence of anti-NKG2D antibody. Figure 4D shows that,
even when NKG2D signaling was blocked, m152/gp40 generally had a greater impact on CTL lysis than m06/gp48. We
conclude that m152/gp40’s disproportionate impact on CTL
lysis cannot be explained solely by its ability to inhibit NKG2D
ligand costimulation.
Impact of NKG2D on CTL lysis with different mouse strains
and cell types. We considered the possibility that NKG2D
signaling might play a greater role in CD8 T-cell lysis of primary rather than transformed cells or, possibly, of different cell
types. To investigate this, we generated bone marrow macrophages (BMM⌽) and primary MEFs from C57BL/6 mice for
use as target cells in the 51Cr release assays. CD8 T-cell lines
were generated against M38 and M97, and 51Cr release assays
were performed in the presence of blocking anti-NKG2D antibody or rat IgG as described above. Figure 5A shows that
blocking NKG2D resulted in some inhibition of lysis by M97specific CTL in MEF and BMM⌽ targets and by M38-specific
CTL in MEFs. However, as was seen with the IC-21 cells, the
impact of NKG2D blockade was modest and made only a small
contribution to the ability of m152/gp40 to affect CTL killing.
To test the impact of NKG2D blockade in a different mouse
strain, we generated BMM⌽ cells and MEFs from BALB/c
mice. Flow cytometry staining for the expression of NKG2D
ligands on BALB/c MEFs and BMM⌽ cells revealed that H60
was downregulated by MCMV infection, but as expected, the
downregulation was independent of m152/gp40 (data not
shown). CD8 T-cell lines were generated against H-2d-restricted M45 and pp89 peptides, and 51Cr release assays performed as described above (Fig. 5B). In this instance, we saw
no impact on killing in the presence of blocking anti-NKG2D
12568
PINTO ET AL.
J. VIROL.
FIG. 4. The impact of the inhibition of NKG2D on CD8 T-cell killing in the presence and absence of m152. (A) Representative 51Cr release
assay in the presence of 50 ␮g/ml of anti-NKG2D. (B) CTL lysis in the presence of anti-NKG2D (open bars) or control IgG (solid bars). ⫹m152
and ⫺m152 indicate the expression of m152 in the viruses used in each group. At least three 51Cr assays were completed for each epitope, and
the results normalized by expressing the lysis of each data point as a percentage of the lysis of ⌬m4 m6 m152 with control IgG. The means ⫾
standard errors of the means of the normalized results from at least three assays per group using an E/T ratio that was off the maximal plateau
are shown. A significant difference (P ⬍ 0.05) between lysis in the presence and absence of NKG2D blockade is indicated by an asterisk. (C) Direct
comparison of the impacts of m152/gp40 and NKG2D blockade on cytolysis by M97-specific T cells. The data shown in panel B are regraphed to
compare virus pairs that differ only by the absence or presence of m152 with and without NKG2D blockade. Error bars show the means ⫾ standard
errors of the means. (D) Comparison of the effects of m152/gp40 or m06/gp48 alone in the presence of anti-NKG2D. The data shown in panel B
are regraphed to compare the impacts of m152/gp40 and m06/gp48 when NKG2D inhibition is playing no role. Error bars show the means ⫾
standard errors of the means.
VOL. 81, 2007
NKG2D SIGNALING IN CTL LYSIS OF MCMV-INFECTED CELLS
12569
that CTL specific for different MCMV epitopes differed in
their susceptibility to NKG2D blockade (Fig. 4). We thought
that costimulation via NKG2D might be required only when
the target cell presents a low-avidity peptide target for the
T-cell receptor (TCR). We postulated that those MCMV-specific CTL that were affected by NKG2D might be specific for
epitopes that are poorly presented by infected cells, resulting in
a suboptimal number of peptide-MHC complexes at the cell
surface. To test this idea, we performed a CTL assay in the
presence or absence of anti-NKG2D using IC-21 targets incubated with a range of peptide concentrations. If NKG2D costimulation contributes to CD8 T-cell activation when the peptide-MHC density is low, we expected that anti-NKG2D would
inhibit lysis at lower peptide concentrations. However, Fig. 6
shows that anti-NKG2D did not inhibit CTL lysis at any concentration of peptide on uninfected IC-21 cells for any of the
epitopes tested.
DISCUSSION
FIG. 5. The effect of NKG2D costimulation on CD8 T-cell killing
in different cell types and mouse strains. (A) 51Cr release assay using
M38- and M97-specific T-cell lines and C57BL/6 MEF and primary
BMM⌽ targets, infected as indicated in the presence of 50 ␮g/ml of
anti-NKG2D (open symbol) or control IgG antibody (closed symbol).
(B) CD8 T-cell lines specific for pp89 and M45 were generated from
BALB/c mice and used in 51Cr release assays with BALB/c MEF and
primary BMM⌽ targets with anti-NKG2D or control antibody as described for panel A.
antibody. We conclude that NKG2D signaling has a small but
perceptible impact on killing of MCMV-infected macrophages
or fibroblasts from C57BL/6 mice but no impact on killing of
infected primary cells generated from BALB/c mice.
The impact of NKG2D blockade is not determined by peptide-MHC density. Finally, we were intrigued by the finding
The fact that m152/gp40’s efficacy in inhibiting CD8 T-cell
function seems greater than its impact on MHC class I levels
has been noted by several investigators (18, 20, 31, 35). A
simple explanation for this discrepancy seemed to be offered by
the finding that, in addition to targeting MHC class I, m152/
gp40 could also target the RAE-1 family of NKG2D ligands.
Since activated CD8 T cells express NKG2D, inhibition of
NKG2D’s costimulatory activity seemed a likely explanation
for m152/gp40’s disproportionate impact on CTL lysis. This
explanation was rendered even more plausible by the clear
demonstration of the importance of NKG2D costimulation in
enabling the lysis of HCMV-infected targets by two pp65specific CTL clones (14). However, the data presented here do
not support this hypothesis. NKG2D inhibition did impact lysis
by CTL specific for four epitopes, M97, M38, m141, and m139.
Notably, this inhibition was only seen for targets infected with
viruses lacking m152, confirming that m152/gp40 effectively
inhibits the majority of NKG2D ligand expression in the IC-21
cells used in this assay. However, NKG2D inhibition had no
impact on CTL lysis by polyclonal CTL lines specific for many
of the MCMV epitopes tested (Fig. 4B). For the epitope specificities for which NKG2D blockade did inhibit lysis, NKG2D
blockade had a smaller impact on target lysis than did adding
FIG. 6. The effect of peptide density on anti-NKG2D inhibition of CTL killing. IC-21 targets, incubated with peptides as indicated, were tested
for lysis by antigen-specific CD8 T cells in the presence of anti-NKG2D or IgG control.
12570
PINTO ET AL.
m152 to the genes expressed by MCMV (Fig. 4C). When we
directly compared the efficacies of m152/gp40 and m06/gp48 at
inhibiting lysis in the presence of NKG2D blockade, it was
evident that m152/gp40’s impact on CTL lysis was greater than
that of m06/gp48 (Fig. 4D), despite the fact that m06/gp48 has
a greater impact on cell surface MHC class I levels (31, 35).
m152/gp40’s disproportionate impact must therefore have another explanation. One possibility would be that, acting at the
peptide-loading complex, m152/gp40 has some level of peptide
cargo discrimination, perhaps more effectively impacting higher-affinity epitopes that are likely to become immunodominant. Another possibility would be that m152/gp40 has yet
further cellular targets that impact CTL efficacy. It is becoming
apparent that some MCMV immune evasion genes do indeed
have multiple cellular targets: for example, m152/gp40 targets
MHC class I and RAE-1. The mechanism of m152/gp40’s disproportionate impact thus requires further investigation.
It was surprising to note that NKG2D inhibition impacted
CTL lysis by T-cell lines specific for only a subset of epitopes.
The reason for this selectivity remains unclear. NKG2D seems
to play a costimulatory role when TCR stimulation might be
suboptimal, such as in tumor or autoimmune epitopes. The
initial observation that NKG2D provided necessary costimulation for HCMV-infected targets seemed in keeping with this
idea, since HCMV profoundly downregulates MHC class I.
Hence, we suspected that the MCMV epitopes affected might
be those that presented lower-avidity ligands for CTL, either
because they were present at low epitope density on the surface of infected targets or because they presented low-affinity
ligands for the TCR. We have not directly assessed the affinity
of peptide-MHC for the TCR. However, we note that the
epitopes that were affected by NKG2D were not obviously of
low affinity for the TCR, as assessed by peptide titration (compare Fig. 4 and 6). Furthermore, peptide titration on IC-21
cells in the presence or absence of NKG2D blockade provided
no evidence for the hypothesis that NKG2D costimulation
would prove crucial when peptide MHC density is limiting, at
least for the target cells used in this assay. Hence, the reason
for NKG2D’s affecting only a minority of epitopes remains
unclear.
Finally, our studies of NKG2D expression on MCMV-specific CD8 T cells revealed an unexpected feature. NKG2D was
expressed on the majority of memory CD8 T cells by 3 weeks
postinfection. However, the rate at which CD8 T cells specific
for different epitopes acquired NKG2D was quite different:
m139- and m141-specific CD8 T cells were almost entirely
NKG2D positive by day 7 postinfection, whereas the total
population of CD8 T cells specific for M38 and M45 took much
longer to become positive. This difference does not correlate
with continued activation during the chronic phase of infection. Responses to both M38 and m139 undergo pronounced
“memory inflation,” whereas responses to both M45 and m141
contract severely in the chronic phase. m139 and m141 are
both members of the same gene family and appear to play an
important role in macrophage tropism, whereas M45 is involved in endothelial cell tropism, and the role of M38 is not
known. Hence, one possible explanation for these epitopespecific differences could be the types of target cells that express greater quantities of the antigens in vivo. This speculation obviously requires further investigation. We do note,
J. VIROL.
however, that the slow rate of acquisition of NKG2D positivity
by M45- and M38-specific CD8 T cells is the exception to the
rapid acquisition of NKG2D that has been more commonly
described in the literature.
The importance of NKG2D in CMV biology can be deduced
from the number of genes that both MCMV and HCMV
devote to downregulating its ligands. Inhibition of NKG2D
signaling has a major impact on the efficacy of murine NK cells,
resulting in significantly higher virus titers in the first few days
of infection. Our data suggest that NKG2D signaling in NK
cells is likely the major focus of the viral genes that inhibit
NKG2D ligands and that targeting NKG2D on CD8 T cells has
only a minor impact on CTL function.
ACKNOWLEDGMENTS
This research was support by the National Institutes of Health
(grants AI47206A and AI50099A to A.B.H.), an American Heart Association fellowship (0215188Z to A.K.P.), and a National Eye Institute training grant (grant ACAEI0071 to A.K.P.).
REFERENCES
1. Bauer, S., V. Groh, J. Wu, A. Steinle, J. H. Phillips, L. L. Lanier, and T.
Spies. 1999. Activation of NK cells and T cells by NKG2D, a receptor for
stress-inducible MICA. Science 285:727–729.
2. Bouwer, H. G., M. S. Seaman, J. Forman, and D. J. Hinrichs. 1997. MHC
class Ib-restricted cells contribute to antilisterial immunity: evidence for
Qa-1b as a key restricting element for Listeria-specific CTLs. J. Immunol.
159:2795–2801.
3. Brune, W., H. Hengel, and U. H. Koszinowski. 2005. A mouse model for
cytomegalovirus infection, unit 19.7. In J. E. Coligan et al. (ed.), Current
protocols in immunology, vol. 4. John Wiley & Sons, Hoboken, NJ.
4. Cavanaugh, V. J., R. M. Stenberg, T. L. Staley, H. W. Virgin IV, M. R.
MacDonald, S. Paetzold, H. E. Farrell, W. D. Rawlinson, and A. E.
Campbell. 1996. Murine cytomegalovirus with a deletion of genes spanning HindIII-J and -I displays altered cell and tissue tropism. J. Virol.
70:1365–1374.
5. Cerwenka, A., A. B. Bakker, T. McClanahan, J. Wagner, J. Wu, J. H.
Phillips, and L. L. Lanier. 2000. Retinoic acid early inducible genes define a
ligand family for the activating NKG2D receptor in mice. Immunity 12:721–
727.
6. del Val, M., H. Hengel, H. Hacker, U. Hartlaub, T. Ruppert, P. Lucin, and
U. H. Koszinowski. 1992. Cytomegalovirus prevents antigen presentation by
blocking the transport of peptide-loaded major histocompatibility complex
class I molecules into the medial-Golgi compartment. J. Exp. Med. 176:729–
738.
7. Del Val, M., H. Volkmer, J. B. Rothbard, S. Jonjic, M. Messerle, J. Schickedanz, M. J. Reddehase, and U. H. Koszinowski. 1988. Molecular basis for
cytolytic T-lymphocyte recognition of the murine cytomegalovirus immediate-early protein pp89. J. Virol. 62:3965–3972.
8. Diefenbach, A., J. K. Hsia, M. Y. Hsiung, and D. H. Raulet. 2003. A novel
ligand for the NKG2D receptor activates NK cells and macrophages and
induces tumor immunity. Eur. J. Immunol. 33:381–391.
9. Diefenbach, A., A. M. Jamieson, S. D. Liu, N. Shastri, and D. H. Raulet.
2000. Ligands for the murine NKG2D receptor: expression by tumor cells
and activation of NK cells and macrophages. Nat. Immunol. 1:119–126.
10. Diefenbach, A., E. Tomasello, M. Lucas, A. M. Jamieson, J. K. Hsia, E.
Vivier, and D. H. Raulet. 2002. Selective associations with signaling proteins
determine stimulatory versus costimulatory activity of NKG2D. Nat. Immunol. 3:1142–1149.
11. Driessen, C., R. A. Bryant, A. M. Lennon-Dumenil, J. A. Villadangos, P. W.
Bryant, G. P. Shi, H. A. Chapman, and H. L. Ploegh. 1999. Cathepsin S
controls the trafficking and maturation of MHC class II molecules in dendritic cells. J. Cell Biol. 147:775–790.
12. Gasser, S., S. Orsulic, E. J. Brown, and D. H. Raulet. 2005. The DNA
damage pathway regulates innate immune system ligands of the NKG2D
receptor. Nature 436:1186–1190.
13. Gold, M. C., M. W. Munks, M. Wagner, C. W. McMahon, A. Kelly, D. G.
Kavanagh, M. K. Slifka, U. H. Koszinowski, D. H. Raulet, and A. B. Hill.
2004. Murine cytomegalovirus interference with antigen presentation has
little effect on the size or the effector memory phenotype of the CD8 T cell
response. J. Immunol. 172:6944–6953.
14. Groh, V., R. Rhinehart, J. Randolph-Habecker, M. S. Topp, S. R. Riddell,
and T. Spies. 2001. Costimulation of CD8alphabeta T cells by NKG2D via
engagement by MIC induced on virus-infected cells. Nat. Immunol. 2:255–
260.
VOL. 81, 2007
NKG2D SIGNALING IN CTL LYSIS OF MCMV-INFECTED CELLS
15. Hardy, R. 1986. Purification and coupling of fluorescent proteins for use in
flow cytometry, 4th ed. Blackwell Scientific Publications, Boston, MA.
16. Hasan, M., A. Krmpotic, Z. Ruzsics, I. Bubic, T. Lenac, A. Halenius, A.
Loewendorf, M. Messerle, H. Hengel, S. Jonjic, and U. H. Koszinowski.
2005. Selective down-regulation of the NKG2D ligand H60 by mouse cytomegalovirus m155 glycoprotein. J. Virol. 79:2920–2930.
17. Holtappels, R., D. Gillert-Marien, D. Thomas, J. Podlech, P. Deegen, S.
Herter, S. A. Oehrlein-Karpi, D. Strand, M. Wagner, and M. J. Reddehase.
2006. Cytomegalovirus encodes a positive regulator of antigen presentation.
J. Virol. 80:7613–7624.
18. Holtappels, R., J. Podlech, M.-F. Pahl-Seibert, M. Julch, D. Thomas, C. O.
Simon, M. Wagner, and M. J. Reddehase. 2004. Cytomegalovirus misleads
its host by priming of CD8 T cells specific for an epitope not presented in
infected tissues. J. Exp. Med. 199:131–136.
19. Jamieson, A. M., A. Diefenbach, C. W. McMahon, N. Xiong, J. R. Carlyle,
and D. H. Raulet. 2002. The role of the NKG2D immunoreceptor in immune
cell activation and natural killing. Immunity 17:19–29.
20. Kavanagh, D. G., M. C. Gold, M. Wagner, U. H. Koszinowski, and A. B. Hill.
2001. The multiple immune-evasion genes of murine cytomegalovirus are
not redundant: m4 and m152 inhibit antigen presentation in a complementary and cooperative fashion. J. Exp. Med. 194:967–978.
21. Kavanagh, D. G., U. H. Koszinowski, and A. B. Hill. 2001. The murine
cytomegalovirus immune evasion protein m4/gp34 forms biochemically distinct complexes with class I MHC at the cell surface and in a pre-Golgi
compartment. J. Immunol. 167:3894–3902.
22. Kleijnen, M. F., J. B. Huppa, P. Lucin, S. Mukherjee, H. Farrell, A. E.
Campbell, U. H. Koszinowski, A. B. Hill, and H. L. Ploegh. 1997. A mouse
cytomegalovirus glycoprotein, gp34, forms a complex with folded class I
MHC molecules in the ER which is not retained but is transported to the cell
surface. EMBO J. 16:685–694.
23. Krmpotic, A., D. H. Busch, I. Bubic, F. Gebhardt, H. Hengel, M. Hasan, A. A.
Scalzo, U. H. Koszinowski, and S. Jonjic. 2002. MCMV glycoprotein gp40
confers virus resistance to CD8⫹ T cells and NK cells in vivo. Nat. Immunol.
3:529–535.
24. Krmpotic, A., M. Hasan, A. Loewendorf, T. Saulig, A. Halenius, T. Lenac, B.
Polic, I. Bubic, A. Kriegeskorte, E. Pernjak-Pugel, M. Messerle, H. Hengel,
D. H. Busch, U. H. Koszinowski, and S. Jonjic. 2005. NK cell activation
through the NKG2D ligand MULT-1 is selectively prevented by the glycoprotein encoded by mouse cytomegalovirus gene m145. J. Exp. Med. 201:
211–220.
25. Lenac, T., M. Budt, J. Arapovic, M. Hasan, A. Zimmermann, H. Simic, A.
Krmpotic, M. Messerle, Z. Ruzsics, U. H. Koszinowski, H. Hengel, and S.
Jonjic. 2006. The herpesviral Fc receptor fcr-1 down-regulates the NKG2D
ligands MULT-1 and H60. J. Exp. Med. 203:1843–1850.
26. Lodoen, M., K. Ogasawara, J. A. Hamerman, H. Arase, J. P. Houchins, E. S.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
12571
Mocarski, and L. L. Lanier. 2003. NKG2D-mediated natural killer cell
protection against cytomegalovirus is impaired by viral gp40 modulation of
retinoic acid early inducible 1 gene molecules. J. Exp. Med. 197:1245–1253.
Lodoen, M. B., G. Abenes, S. Umamoto, J. P. Houchins, F. Liu, and L. L.
Lanier. 2004. The cytomegalovirus m155 gene product subverts natural killer
cell antiviral protection by disruption of H60-NKG2D interactions. J. Exp.
Med. 200:1075–1081.
Loh, L. C., N. Balachandran, and L. F. Qualtiere. 1988. Characterization of
a major virion envelope glycoprotein complex of murine cytomegalovirus
and its immunological cross-reactivity with human cytomegalovirus. Virology
166:206–216.
Loh, L. C., and L. F. Qualtiere. 1988. A neutralizing monoclonal antibody
recognizes an 87K envelope glycoprotein on the murine cytomegalovirus
virion. Virology 162:498–502.
LoPiccolo, D. M., M. C. Gold, D. G. Kavanagh, M. Wagner, U. H. Koszinowski, and A. B. Hill. 2003. Effective inhibition of Kb- and Db-restricted
antigen presentation in primary macrophages by murine cytomegalovirus.
J. Virol. 77:301–308.
Pinto, A. K., M. W. Munks, U. H. Koszinowski, and A. B. Hill. 2006.
Coordinated function of murine cytomegalovirus genes completely inhibits
CTL lysis. J. Immunol. 177:3225–3234.
Rapp, M., P. Lucin, M. Messerle, L. C. Loh, and U. H. Koszinowski. 1994.
Expression of the murine cytomegalovirus glycoprotein H by recombinant
vaccinia virus. J. Gen. Virol. 75:183–188.
Reusch, U., W. Muranyi, P. Lucin, H. G. Burgert, H. Hengel, and U. H.
Koszinowski. 1999. A cytomegalovirus glycoprotein re-routes MHC class I
complexes to lysosomes for degradation. EMBO J. 18:1081–1091.
Thale, R., U. Szepan, H. Hengel, G. Geginat, P. Lucin, and U. H. Koszinowski. 1995. Identification of the mouse cytomegalovirus genomic region
affecting major histocompatibility complex class I molecule transport. J. Virol. 69:6098–6105.
Wagner, M., A. Gutermann, J. Podlech, M. J. Reddehase, and U. H. Koszinowski. 2002. Major histocompatibility complex class I allele-specific cooperative and competitive interactions between immune evasion proteins of
cytomegalovirus. J. Exp. Med. 196:805–816.
Wagner, M., S. Jonjic, U. H. Koszinowski, and M. Messerle. 1999. Systematic
excision of vector sequences from the BAC-cloned herpesvirus genome
during virus reconstitution. J. Virol. 73:7056–7060.
Yewdell, J. W., and A. B. Hill. 2002. Viral interference with antigen presentation. Nat. Immunol. 3:1019–1025.
Ziegler, H., R. Thale, P. Lucin, W. Muranyi, T. Flohr, H. Hengel, H. Farrell,
W. Rawlinson, and U. H. Koszinowski. 1997. A mouse cytomegalovirus
glycoprotein retains MHC class I complexes in the ERGIC/cis-Golgi compartments. Immunity 6:57–66.